



Article

# Four Prenylflavone Derivatives with Antiplasmodial Activities from the Stem of *Tephrosia purpurea* subsp. *leptostachya*

Yoseph Atilaw <sup>1</sup>, Lois Muiva-Mutisya <sup>1</sup>, Albert Ndakala <sup>1</sup>, Hoseah M. Akala <sup>2</sup>, Redemptah Yeda <sup>2</sup>, Yu J. Wu <sup>3</sup>, Paolo Coghi <sup>3</sup> , Vincent K. W. Wong <sup>3</sup>, Máté Erdélyi <sup>4,5,\*</sup>  and Abiy Yenesew <sup>1,\*</sup>

<sup>1</sup> Department of Chemistry, University of Nairobi, Nairobi, P.O. Box 30197-00100, Kenya;

gebreyos@gmail.com (Y.A.); loismwikali@yahoo.com (L.M.-M.); andakala@uonbi.ac.ke (A.N.)

<sup>2</sup> Global Emerging Infections Surveillance (GEIS) Program, United States Army Medical Research Unit-Kenya (USAMRU-K), Kenya Medical Research Institute (KEMRI)—Walter Reed Project, Kisumu and Nairobi, P.O. Box 54-40100, Kisumu, Kenya; hoseaakala@yahoo.com (H.M.A.); redemptah.yeda@usamru-k.org (R.Y.)

<sup>3</sup> State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, P.O. Box 999078, China; yuki-ng92@hotmail.com (Y.J.W.); bowaiwong@gmail.com (V.K.W.W.); vecchioco@gmail.com (P.C.)

<sup>4</sup> Department of Chemistry and Molecular Biology, University of Gothenburg, SE-40530 Gothenburg, Sweden

<sup>5</sup> Swedish NMR Centre, University of Gothenburg, P.O. Box 465, SE-40530 Gothenburg, Sweden

\* Correspondence: mate.erdelyi@kemi.uu.se (M.E.); ayenesew@uonbi.ac.ke (A.Y.);  
Tel.: +46-72-999-9166 (M.E.); +254-73-383-2576(A.Y.); Fax: +254-20-444-6138 (A.Y.)

Received: 28 July 2017; Accepted: 6 September 2017; Published: 10 September 2017

**Abstract:** Four new flavones with modified prenyl groups, namely (*E*)-5-hydroxytephrostachin (**1**), purleptone (**2**), (*E*)-5-hydroxyanhydrotephrostachin (**3**), and terpurlepflavone (**4**), along with seven known compounds (**5–11**), were isolated from the CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1) extract of the stem of *Tephrosia purpurea* subsp. *leptostachya*, a widely used medicinal plant. Their structures were elucidated on the basis of NMR spectroscopic and mass spectrometric evidence. Some of the isolated compounds showed antiplasmodial activity against the chloroquine-sensitive D6 strains of *Plasmodium falciparum*, with (*E*)-5-hydroxytephrostachin (**1**) being the most active, IC<sub>50</sub> 1.7 ± 0.1 μM, with relatively low cytotoxicity, IC<sub>50</sub> > 21 μM, against four cell-lines.

**Keywords:** *Tephrosia purpurea* subsp. *leptostachya*; stem; flavone; antiplasmodial; cytotoxicity

## 1. Introduction


*Tephrosia purpurea* (family Leguminosae) is one of the most widely distributed *Tephrosia* species and is found in tropical, subtropical, and other arid parts of the world. It consists of the four subspecies *purpurea*, *leptostachya*, *appolinea*, and *barbigera*, and four varieties, namely under subsp. *leptostachya* var. *leptostachya* and var. *pubescens*, and under subsp. *barbigera* var. *barbigera* and var. *rufescens* [1–5]. In Africa, a decoction of roots, leaves, and fruits of *Tephrosia purpurea* is given as a diuretic, for blood purification, and for the treatment of a cough and cold [6]. Its macerated leaves are used for curing diarrhoea and whooping cough in children [6]. In East Africa, its roots are used against stomach pains, while its leaves are used to treat snake bites and headaches. A decoction of its leaves and roots is used as a purgative [7], whereas that of the roots of *T. purpurea* subsp. *leptostachya* is employed for the treatment of schistosomiasis [6].

Phytochemical studies on *T. purpurea* collected from different parts of the world have resulted in the isolation of a wide variety of flavonoids; flavones [8,9], rotenoids [10], chalcones [11], and flavanones [12]. The crude extracts and pure compounds obtained from *T. purpurea* have shown

a wide range of biological activities including antiplasmodial [12,13], anticancer [14], antacid [15], antidiabetic [16], analgesic and anti-inflammatory [17], and hepatoprotective [18] activities, and were also shown to be applicable to treat *Helicobacter pylori* infection [19]. Despite the presence of several subspecies and varieties of the taxa *T. purpurea*, the ethnobotanical, bioactivity, and phytochemical reports available so far have not been specific on the particular subspecies and variety. In order to better understand the relationship between *T. purpurea* and other species, the chemical variability among its subspecies and varieties has to be documented. With this in mind, the first phytochemical and biological report on *T. purpurea* subsp. *leptostachya* is reported here.

## 2. Results and Discussion

Extraction of the air dried stem of *T. purpurea* subsp. *leptostachya* with  $\text{CH}_2\text{Cl}_2/\text{MeOH}$  (1:1) at room temperature, followed by a combination of chromatographic separations, gave four new (1–4) and seven known (5–11) compounds (Figure 1).



**Figure 1.** Structures of compounds isolated from *T. purpurea* subsp. *leptostachya*.

Compound 1 was isolated as yellow crystals, and its molecular formula  $\text{C}_{21}\text{H}_{20}\text{O}_5$  was established from HRMS ( $m/z$  352.1315) and  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR data (Table 1, Figures S1–S6). The UV ( $\lambda_{\text{max}}$  230, 270 and 310 nm),  $^1\text{H}$  ( $\delta_{\text{H}}$  6.67 for H-3), and  $^{13}\text{C}$  ( $\delta_{\text{C}}$  164.2 for C-2, 105.5 for C-3, and 182.9

for C-3) NMR spectral data suggested that this compound is a flavone derivative substituted with methoxy ( $\delta_{\text{H}}$  3.92;  $\delta_{\text{C}}$  56.1), hydrogen bonded hydroxyl ( $\delta_{\text{H}}$  13.08), and 2-methylbut-3-en-2-ol (Table 1, Tables S1–S6) substituents. The HMBC correlation of H-3 ( $\delta_{\text{H}}$  6.67) with C-2 ( $\delta_{\text{C}}$  164.2), C-4 ( $\delta_{\text{C}}$  182.9), and C-4a ( $\delta_{\text{C}}$  105.2) further supported the proposed flavone structure. Three sets of mutually coupled protons resonating at  $\delta_{\text{H}}$  7.91 (H-2'/6'), 7.52 (H-3'/5'), and 7.55 (H-4') with corresponding carbons at  $\delta_{\text{C}}$  126.5 (C-2'/6'), 129.1 (C-3'/5'), and 131.9 (C-4'), respectively, were assigned to ring-B, which is unsubstituted (Table 1). The  $^1\text{H-NMR}$  data (Table 1) of **1** possesses a singlet at  $\delta_{\text{H}}$  6.40 ( $\delta_{\text{C}}$  95.3) on ring-A, which is hence trisubstituted with a methoxy (at C-7), a hydrogen bonded hydroxy (at C-5), and a (*E*)-2-methylbut-3-en-2-ol group. The HMBC correlations of the singlet at  $\delta_{\text{H}}$  6.40 with C-4a ( $\delta_{\text{C}}$  105.2), C-5 ( $\delta_{\text{C}}$  161.3), C-7 ( $\delta_{\text{C}}$  163.1), and C-8 ( $\delta_{\text{C}}$  105.3) allowed its assignment to H-6. Based on HMBC correlations, the methoxy group ( $\delta_{\text{H}}$  3.92,  $\delta_{\text{C}}$  56.1) was placed at C-7 ( $\delta_{\text{C}}$  163.1) and the hydrogen bonded hydroxy group ( $\delta_{\text{H}}$  13.08) at C-5, and the 2-methylbut-3-en-2-ol group could only be placed at C-8. This regiochemistry was confirmed by the HMBC correlation of OH-5 ( $\delta_{\text{H}}$  13.08) to C-4a ( $\delta_{\text{C}}$  105.2), C-5 ( $\delta_{\text{C}}$  161.3), and C-6 ( $\delta_{\text{C}}$  95.3)], and of the olefinic proton H-1'' ( $\delta_{\text{H}}$  6.85) to C-7 ( $\delta_{\text{C}}$  163.1) and C-8a ( $\delta_{\text{C}}$  154.1). The  $J = 16.5$  Hz coupling between H-1'' ( $\delta_{\text{H}}$  6.85) and H-2'' ( $\delta_{\text{H}}$  6.70) is consistent with the *E*-configuration of the double bond of the 2-methylbut-3-en-2-ol group [20]. Therefore, compound **1** was characterized as (*E*)-5-hydroxy-8-(3-hydroxy-3-methylbut-1-en-1-yl)-7-methoxy-2-phenyl-4*H*-chromen-4-one. It is a 5-hydroxy derivative of *trans*-tephrostachin [20] and hence was given the trivial name (*E*)-5-hydroxytephrostachin.

The molecular formula of compound **2** was established as  $\text{C}_{20}\text{H}_{16}\text{O}_5$  from HRMS ( $m/z$  336.0980), and  $^1\text{H-}$  and  $^{13}\text{C-NMR}$  data (Table 1, Figures S9–S13). Its UV spectrum ( $\lambda_{\text{max}}$  230, 290, and 330 nm), along with its NMR spectra (Table 1), suggested that **2** had a flavone skeleton. Its  $^1\text{H-}$  and  $^{13}\text{C-NMR}$  spectra (Table 1) showed high similarities to those of **1**. Thus, ring-B of **2** is unsubstituted, while its ring-A is trisubstituted, with a hydroxy at C-5, a methoxy at C-7, and a modified prenyl group at C-8 (Table 1). The  $^1\text{H-NMR}$  spectral data further suggested the presence of *trans*-oriented and mutually coupled ( $J = 16.4$  Hz) olefinic protons, which are deshielded ( $\delta_{\text{H}}$  8.06, H-1'', and  $\delta_{\text{H}}$  7.18, H-2''), suggesting a different substituent at C-8 of **2** as compared to **1**. Furthermore, a single, deshielded methyl signal ( $\delta_{\text{H}}$  2.41;  $\delta_{\text{C}}$  27.8) was observed, which along with an additional carbonyl signal ( $\delta_{\text{C}}$  199.1) showing HMBC correlations to H-1'' ( $\delta_{\text{H}}$  8.06) and H-2'' ( $\delta_{\text{H}}$  7.18), suggests that the C-8 substituent is the rare (*E*)-but-3-en-2-one group, similar to that reported for (2*S*)-5-hydroxy-7-methoxy-8-[(*E*)-3-oxo-1-butenyl]flavanone [21], and for erylivingstone F [22]. Based on the above spectroscopic data, compound **2** was characterized as (*E*)-5-hydroxy-7-methoxy-8-(3-oxobut-1-en-1-yl)-2-phenyl-4*H*-chromen-4-one and was given the trivial name purleptone.

Compound **3** ( $[\text{M} + 1]^+$   $m/z$  335.1227,  $\text{C}_{21}\text{H}_{18}\text{O}_4$ ) was also found to be a flavone derivative ( $\lambda_{\text{max}}$  230, 280 and 310 nm), whose  $^1\text{H-}$  and  $^{13}\text{C-NMR}$  spectra (Table 1, Figures S16–S21) showed close similarities to those of **1** and **2**. It was found to have an unsubstituted ring-B, and trisubstituted ring-A with hydroxy at C-5, methoxy at C-7, and a modified prenyl group at C-8. The structure of the latter substituent was established to be (*E*)-3-methylbuta-1,3-dien-1-yl from the  $^1\text{H-}$  and  $^{13}\text{C-NMR}$  spectral data (Table 1), and was confirmed by the HMBC correlations of  $\text{CH}_2$ -4'' ( $\delta_{\text{H}}$  5.10) with C-2'' ( $\delta_{\text{C}}$  135.4), C-3'' ( $\delta_{\text{C}}$  142.9), and C-5'' ( $\delta_{\text{C}}$  18.2). The placement of this group at C-8 was established from the HMBC correlations of H-2'' ( $\delta_{\text{H}}$  6.29) to C-8 ( $\delta_{\text{C}}$  106.0), C-3'' ( $\delta_{\text{C}}$  142.9), C-4'' ( $\delta_{\text{C}}$  116.8), and C-5'' ( $\delta_{\text{C}}$  18.2), and of H-5'' ( $\delta_{\text{H}}$  2.06) with C-2'' ( $\delta_{\text{C}}$  135.4), C-3'' ( $\delta_{\text{C}}$  142.9), and C-4'' ( $\delta_{\text{C}}$  116.8). In agreement with this, H-1'' also showed HMBC correlation with C-7 ( $\delta_{\text{C}}$  163.2), C-8a ( $\delta_{\text{C}}$  154.2), C-2'' ( $\delta_{\text{C}}$  135.4), and C-3'' ( $\delta_{\text{C}}$  142.9). Compound **3** was therefore characterized as (*E*)-5-hydroxy-7-methoxy-8-(3-methylbuta-1,3-dien-1-yl)-2-phenyl-4*H*-chromen-4-one, and was given the trivial name (*E*)-5-hydroxyanhydrotephrostachin as it is structurally closely related to anhydrotephrostachin [20].

**Table 1.**  $^1\text{H}$ - (800 MHz) and  $^{13}\text{C}$ - (200 MHz) NMR data for compounds **1**, **2**, and **3** (in  $\text{CDCl}_3$ ) at 25 °C.

Position	1			2			3		
	$\delta_{\text{C}}$ (ppm)	$\delta_{\text{H}}$ , <i>m</i> (J in Hz)	HMBC (H→C)	$\delta_{\text{C}}$	$\delta_{\text{H}}$ , <i>m</i> (J in Hz)	HMBC (H→C)	$\delta_{\text{C}}$	$\delta_{\text{H}}$ , <i>m</i> (J in Hz)	HMBC (H→C)
2	164.2			164.6			164.2		
3	105.5	6.57 <i>s</i>	C-2, C-4, C-4a, C-1'	106.2	6.74 <i>s</i>	C-2, C-4, C-4a, C-1'	105.5	6.71 <i>s</i>	C-2, C-4, C-4a, C-1'
4	182.9			182.6			183.0		
4a	105.2			105.4			105.3		
5	161.3			164.2			161.4		
5-OH		13.08 <i>s</i>	C-4a, C-5, C-6		13.41 <i>s</i>	C-4a, C-5, C-6		13.11 <i>s</i>	C-4a, C-5, C-6
6	95.3	6.40 <i>s</i>	C-4a, C-5, C-7, C-8	95.6	6.40 <i>s</i>	C-4a, C-5, C-7, C-8	95.4	6.45 <i>s</i>	C-4a, C-5, C-7, C-8
7	163.1			165.0			163.2		
8	105.3			103.4			106.0		
8a	154.1			156.0			154.2		
1'	131.5			131.5			131.5		
2',6'	126.5	7.91 <i>m</i>	C-2, C-4', C-2', C-6'	126.5	7.92 <i>m</i>	C-2, C-4', C-2', C-6'	126.4	7.93 <i>m</i>	C-2, C-4', C-2', C-6'
3',5'	129.1	7.52 <i>m</i>	C-1', C-3', C-5'	129.4	7.59 <i>m</i>	C-1', C-3', C-5'	129.2	7.54 <i>m</i>	C-1', C-3', C-5'
4'	131.9	7.55 <i>m</i>	C-2', C-6'	132.2	7.59 <i>m</i>	C-2', C-6'	132.0	7.56 <i>m</i>	C-2', C-6'
1''	114.9	6.85, <i>d</i> (16.5)	C-7, C-8a, C-2'', C-3''	132.0	8.06, <i>d</i> (16.4)	C-7, C-8a, C-2'', C-3''	117.5	6.83, <i>d</i> (16.5)	C-7, C-8a, C-2'', C-3''
2''	141.3	6.70, <i>d</i> (16.5)	C-8, C-3'', 3''-Me <sub>2</sub>	128.8	7.18, <i>d</i> (16.4)	C-8, C-3'', C-4''	135.4	6.29, <i>d</i> (16.5)	C-8, C-3'', C-4'', C-5''
3''	71.5			199.1			142.9		
3''-Me <sub>2</sub>	30.0	1.50 <i>s</i>	C-2'', C-3'', 3''-Me <sub>2</sub>						
4''				27.8	2.41 <i>s</i>	C-2'', C-3''	116.8	5.10 <i>s</i>	C-2'', C-3'', C-5''
5''							18.2	2.06 <i>s</i>	C-2'', C-3'', C-4''
7(OMe)	56.1	3.92 <i>s</i>	C-7	56.4	4.01 <i>s</i>	C-7	56.2	3.97 <i>s</i>	C-7

The structure of compound **4** ( $[M + 1]^+$ ,  $m/z$  423.1465,  $C_{24}H_{22}O_7$ ), also a flavone, was established from  $^1H$ - and  $^{13}C$ -NMR data (Table 2, Figures S24–S29), as well as from its UV spectrum ( $\lambda_{max}$  230, 260, and 310 nm). Its NMR spectra (Table 2) revealed the presence of an unsubstituted ring-B ( $\delta_H$  7.70,  $\delta_C$  126.3 (H-2'/6'),  $\delta_H$  7.45,  $\delta_C$  128.7 (H-3'/5'), and  $\delta_H$  7.49,  $\delta_C$  131.1 (H-4' *m*)), a methoxy ( $\delta_H$  3.96,  $\delta_C$  56.7) at C-5, an acetate [ $(\delta_H$  2.11,  $\delta_C$  21.4 (Me),  $\delta_C$  170.0 (C=O)] at C-7, and a modified prenyl group in the form of a tetrahydrofuran ring at C-8 (Table 2), similar to terpurinflavone [12] and tephroglabrin [23]. The presence of an additional carbonyl ( $\delta_C$  206.1) and two geminal methyl groups ( $\delta_H$  1.57,  $\delta_C$  24.0 and  $\delta_H$  1.65,  $\delta_C$  23.9), and three mutually coupled protons at  $\delta_H$  4.95 (*dd*,  $J = 6.1, 10.2$  Hz),  $\delta_H$  4.90 (*dd*,  $J = 6.1, 8.8$ ) and  $\delta_H$  4.84 (*dd*,  $J = 6.1, 8.8$  Hz) indicated that the C-8 substituent was a 5,5-dimethyl-4-oxo-tetrahydrofuran-3-yl group. In agreement with this, H-4'' ( $\delta_H$  4.95), H-5'' ( $\delta_H$  4.90), and 2''-(Me)<sub>2</sub> ( $\delta_H$  1.57 and 1.65) showed HMBC correlations to the carbonyl carbon C-3'' ( $\delta_C$  206.1). The HMBC correlation of H-4'' ( $\delta_H$  4.95) with C-7; H-6 ( $\delta_H$  6.41) with C-4a ( $\delta_C$  109.1), C-5 ( $\delta_C$  162.9), C-7 ( $\delta_C$  166.3), and C-8 ( $\delta_C$  103.9); and the OMe ( $\delta_H$  3.96) with C-5 ( $\delta_C$  162.9) confirmed the substitution pattern of this ring. The coupling constant  $J = 10.2$  Hz of H-4'' and H-5'' indicated a 1,2-diaxial orientation of these protons [12]. Hence, compound **4** was characterized as 8-(5,5-dimethyl-4-oxotetrahydrofuran-3-yl)-5-methoxy-4-oxo-2-phenyl-4H-chromen-7-yl acetate and was given the trivial name terpurleflavone.

**Table 2.**  $^1H$ - (800 MHz) and  $^{13}C$ - (200 MHz) spectroscopic data for compound **4** ( $CDCl_3$ ) at 25 °C.

Position	$\delta_C$	$\delta_H$ , <i>m</i> ( <i>J</i> in Hz)	HMBC (H→C)
2	160.6		
3	110.1	6.55 <i>s</i>	C-2, C-4, C-4a, C-1'
4	177.2		
4a	109.1		
5	162.9		
6	91.1	6.41 <i>s</i>	C-4a, C-5, C-7, C-8
7	166.3		
8	103.9		
8a	154.9		
1'	131.7		
2',6'	126.3	7.70 <i>m</i>	C-2, C-4', C-2', C-6'
3',5'	128.7	7.45 <i>m</i>	C-1', C-3', C-5'
4'	131.1	7.49 <i>m</i>	C-2', C-6'
2''	83.9		
3''	206.1		
4''	47.7	4.95 <i>dd</i> (10.2, 6.1)	C-7, C-8, C-8a, C-2'', C-3'', C-5''
5''	75.8	4.90 <i>dd</i> (10.2, 8.8)	C-7, C-8, C-3'', C-4''
		4.84 <i>dd</i> (6.1, 8.8)	C-7, C-8, C-3'', C-4''
2''-Me	24.0	1.57 <i>s</i>	C-2'', C-3'', 2''-Me
2''-Me	23.9	1.65 <i>s</i>	C-2'', C-3'', 2''-Me
5-OMe	56.7	3.96 <i>s</i>	C-5
7-COMe	170.0		
7-COMe	21.4	2.11 <i>s</i>	7-COMe

The known compounds were identified as derrone (**5**) [24], glabranin (**6**) [25], obovatin methyl ether (**7**) [26], genistein (**8**) [27], tachrosin (**9**) [28], kaempferitrin (**10**) [29], and D-pinitol (**11**) [30] by a comparison of their spectroscopic data (Tables S1 to S7) with that available in the literature. The major flavones of this plant were tested for antiplasmodial activity against the D6 strain of *Plasmodium falciparum* (Table 3). Among these, (*E*)-5-hydroxytephrostachin (**1**) showed good activity,  $IC_{50}$  1.7  $\mu M$ ), while terpurleflavone (**4**) and tachrosin (**9**) showed low antiplasmodial activities. The compounds were also tested for cytotoxicity against two non-tumoral and two cancerous cell-lines (Table 3). Most of these did not show cytotoxicity ( $IC_{50} > 100 \mu M$ ), while compound **1** showed  $IC_{50}$  between 21–100  $\mu M$ , which is still significantly lower than its antiplasmodial activity with a selectivity

index > 12. The results observed here demonstrate the potential of flavones as antiplasmodial agents, parallel to the in vitro and in vivo antiplasmodial activities reported earlier for some flavones [12,31].

**Table 3.** In vitro antiplasmodial activity and cytotoxicity of compounds **1**, **2**, **4** and **9** (IC<sub>50</sub>, μM).

Samples	Antiplasmodial Activity against <i>P. falciparum</i>		Cytotoxicity		
	D6	LO2 *	BEAS *	A549 **	HepG2 **
(E)-5-Hydroxytephrostachin ( <b>1</b> )	1.7 ± 0.1	21.7 ± 4.8	24.5 ± 2.7	76.1 ± 2.9	>100
Purleptone ( <b>2</b> )	NT	>100	>100	>100	>100
Terpurleflavone ( <b>4</b> )	14.8 ± 3.2	>100	>100	>100	>100
Tachrosin ( <b>9</b> )	27.1 ± 3.2	>100	>100	>100	>100
Chloroquine	0.037 ± 0.003				
Artesunate-Mefloquine	0.075 ± 0.006				

\* Non-tumoral cell: LO2, Immortal human hepatic cell line; BEAS, Lung/bronchus cell line (epithelial virus transformed); \*\* Cancer cell: A549, adenocarcinomic human alveolar basal epithelial cells; HepG2, human liver cancer cell line; NT = Not Tested.

### 3. Materials and Methods

#### 3.1. General Experimental Procedure

UV spectra were recorded on a Specord S600 (Analytik Jena AG, Jena, Germany) spectrophotometer. Melting points were obtained on a Büchi Melting point B-545 (Flawil, Switzerland) apparatus, and optical rotations were measured on Perkin Elmer 341-LC (Perkin Elmer, Wellesley, MA, USA), whereas CD experiments were run on a Jasco J-715 spectropolarimeter (Jasco, Corp., Tokyo, Japan). NMR spectra were acquired on a Bruker Avance III HD 800 spectrometer (Bruker BioSpin AG, Fallanden, Switzerland) equipped with a TXO cryogenic probe using the residual solvent peak as the reference. Analytical reversed phase liquid chromatography (RP-HPLC)—mass spectrometry (MS) was performed on a API SCIEX 150 EX Perkin Elmer (Perkin Elmer, Waltham, MA, USA) ESI-MS (30 eV) connected to a Perkin Elmer gradient pump system and a C8 column (120 Å, 4 μm, 4.6 mm × 50 mm) using gradients of acetonitrile/water (CH<sub>3</sub>CN/H<sub>2</sub>O) with 1% formic acid (HCOOH) as the mobile phase at a flow rate of 1 mL/min. TLC was carried out on Merck pre-coated silica gel 60 F254 plates (Merck, Darmstadt, Germany). Column chromatography was run on silica gel 60 (70–230 mesh). Gel filtration was done on Sephadex LH-20 (Fluka, Buchs, Switzerland). Preparative HPLC was carried out on a Waters 600E instrument using the Chromulan (Pikron Ltd., Praha, Czech Republic) software and a RP-C<sub>8</sub> Kromasil®(250 mm × 55 mm, Kromasil, Bohus, Sweden) column with an H<sub>2</sub>O/MeOH solvent system for elution. HRESIMS were obtained with a Q-TOF-LC/MS spectrometer (Stenhagen Analyslab AB, Gothenburg, Sweden) using a 2.1 mm × 30 mm, 1.7 μm RPC18 column and a H<sub>2</sub>O–CH<sub>3</sub>CN gradient system (5:95–95:5 gradient and 0.2% formic acid).

#### 3.2. Plant Material

The stems of *Tephrosia purpurea* subsp. *leptostachya* were collected in April 2015 from the Kilungu hills in Makueni County, Kenya. The plant specimen was identified by Mr. Patrick C. Mutiso of the Herbarium, School of Biological Sciences, University of Nairobi, where a voucher specimen (Mutiso-841/April 2015) was deposited.

#### 3.3. Extraction and Isolation

The air dried and ground stems (2 kg) of *T. purpurea* subsp. *leptostachya* were extracted with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1) for seven days at 20–25 °C by percolation (3 × 2 L) to yield a dark yellow paste (80 g, 4%). Hence, it was soaked for 24 h with 2 L solvent, filtered, and concentrated using a rotary evaporator. This procedure was then repeated three times. A portion of the extract (31 g) was subjected to column chromatography over silica gel (300 g) eluting with *iso*-hexane containing increasing amounts of EtOAc. The fraction that eluted with 3% EtOAc in *iso*-hexane was purified by

gel filtration on Sephadex LH-20 (eluent: CH<sub>2</sub>Cl<sub>2</sub>/MeOH; 1:1) to give **2** (16.2 mg, ≥97% purity) and **3** (23.4 mg, ≥97% purity). The eluent with 5% EtOAc in *iso*-hexane was first separated over Sephadex LH-20 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH; 1:1) followed by preparative HPLC (20:80 MeOH/H<sub>2</sub>O–100% MeOH gradient elution for 20 min with flow rate 8 mL/min) to give **5** (derrone, 28 mg, ≥98% purity) [24], **6** (glabranin, 52 mg, ≥98% purity) [25], **7** (obovatin methyl ether, 47 mg, ≥99% purity) [26], and **8** (genistein, 53 mg, ≥98% purity) [27]. Elution with 6% EtOAc in *iso*-hexane gave a yellow solid which was recrystallized from CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1) to give **1** (550 mg, ≥99% purity). Further elution with 8% EtOAc in *iso*-hexane gave **4** (67.5 mg, ≥99% purity); the eluent with 9% EtOAc in *iso*-hexane gave **9** (tachrosin, 158 mg, >99% purity) [28]; and the 10% EtOAc in *iso*-hexane eluent gave **10** (kaempferitrin, 97 mg, >99% purity) [29]. Fraction elution with 15% EtOAc in *iso*-hexane gave **11** (D-pinitol, 650 mg, >99% purity) [30].

*(E)*-5-Hydroxytephrostachin (**1**): Yellow crystals (CH<sub>2</sub>Cl<sub>2</sub>/MeOH; 1:1). m.p.t 160–162 °C. UV λ<sub>max</sub> (CH<sub>2</sub>Cl<sub>2</sub>): 230, 270 and 310 nm. <sup>1</sup>H- and <sup>13</sup>C-NMR (Table 1). EIMS *m/z* (rel. int.) 353.6 [M]<sup>+</sup> (100). HRMS [M]<sup>+</sup> *m/z* 352.1315 C<sub>21</sub>H<sub>20</sub>O<sub>5</sub> (Calculated: 352.1311).

Purleptone (**2**): Colourless amorphous solid. UV λ<sub>max</sub> (CH<sub>2</sub>Cl<sub>2</sub>): 230, 290 and 330 nm. <sup>1</sup>H- and <sup>13</sup>C-NMR (Table 1). EIMS *m/z* (rel. int.) 337 [M]<sup>+</sup> (100). HRMS [M]<sup>+</sup> *m/z* 336.0980 C<sub>20</sub>H<sub>16</sub>O<sub>5</sub> (Calculated: 336.0998).

*(E)*-5-Hydroxyanhydrotephrostachin (**3**): Colourless amorphous solid. UV λ<sub>max</sub> (CH<sub>2</sub>Cl<sub>2</sub>): 230, 280 and 310 nm. <sup>1</sup>H- and <sup>13</sup>C-NMR (Table 1). EIMS *m/z* (rel. int.) 336.1276 [M]<sup>+</sup>. HRMS [M + 1]<sup>+</sup> *m/z* 335.1227 C<sub>21</sub>H<sub>18</sub>O<sub>4</sub> (Calculated: 335.1283).

Terpurleptone (**4**): White amorphous solid. m.p.t 210–214 °C. UV λ<sub>max</sub>(CH<sub>2</sub>Cl<sub>2</sub>): 230, 260 and 310 nm. CD (MeOH) λ nm (Δε; M<sup>-1</sup>·cm<sup>-1</sup>): (122.83)<sub>221</sub>; (−58.17)<sub>212</sub>. [α]<sub>D</sub><sup>20</sup> +14.00° (c 0.001, MeOH). <sup>1</sup>H- and <sup>13</sup>C-NMR (Table 2). EIMS *m/z* (rel. int.) 423 [M]<sup>+</sup>. HRMS [M + 1]<sup>+</sup> *m/z* 423.1465 C<sub>24</sub>H<sub>22</sub>O<sub>7</sub> (Calculated: 423.1444).

### 3.4. In Vitro Antiplasmodial Activity

The pure compounds were assayed using a non-radioactive assay technique as described by Smilkstein et al., 2004 [32] with modifications given in the literature [12,33].

### 3.5. Cell Culture

A549, HepG2, and non-tumoral cells were all purchased from ATCC. Cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and antibiotics penicillin (50 U/mL) and streptomycin (50 µg/mL; Invitrogen, Paisley, Scotland, UK). All cell cultures were incubated at 37 °C in a 5% humidified CO<sub>2</sub> incubator.

### 3.6. Cytotoxicity Assay

All tested compounds were dissolved in DMSO at a final concentration of 50 mmol/L and stored at −20 °C before use. Cytotoxicity was assessed by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (5.0 mg/mL) assay as previously described [34]. Briefly, 4 × 10<sup>3</sup> cells per well were seeded in 96-well plates before drug treatments. After overnight culture, the cells were then exposed to different concentrations of selected compounds (0.039–100 µmol/L) for 72 h. Cells without drug treatment were used as the control. Subsequently, MTT (10 µL) solution was added to each well and incubated at 37 °C for 4 h followed by the addition of 100 µL solubilization buffer (10% SDS in 0.01 mol/L HCl) and overnight incubation. A<sub>570</sub> nm was then determined in each well on the next day. The percentage of cell viability was calculated using the following formula: Cell viability (%) = A<sub>treated</sub>/A<sub>control</sub> × 100. Data were obtained from three independent experiments and the standard error was calculated.

#### 4. Conclusions

Four new prenylflavones with seven known compounds were isolated from the stem of *Tephrosia purpurea* subsp. *leptostachya*. The isolated flavones were tested for antiplasmodial activity against the D6 strain of *Plasmodium falciparum*. Among these, (*E*)-5-hydroxytephrostachin (**1**) showed good activity (IC<sub>50</sub> 1.7 μM). The compounds were also tested for cytotoxicity against two non-tumoral and two cancerous cell-lines. Most of these did not show cytotoxicity (IC<sub>50</sub> > 100 μM), while compound **1** showed IC<sub>50</sub> between 21–100 μM.

**Supplementary Materials:** The Supplementary Materials are available online. NMR, UV and MS spectra for all new compounds and spectral data for the known compounds are available as Supporting Information.

**Acknowledgments:** Yoseph Atilaw is grateful to the German Academic Exchange Services (DAAD) for a scholarship which was offered through the Natural Products Research Network for Eastern and Central Africa (NAPRECA). The Swedish Research Council (Swedish Research Links, 2016-05857), the International Science Program (ISP Sweden, grant KEN-02), the Adlerbertska Research Foundation and the Royal Society of Arts and Sciences in Göteborg are acknowledged for financial support. Matthias Heydenreich is thanked for measuring the HRMS for two compounds. Gao Jiaying is acknowledged for technical assistance in the cytotoxicity assay.

**Author Contributions:** The list of authors contributed to this work as follows: Extraction and isolation of compounds was done by Y. Atilaw and L. Muiva-Mutisya; spectroscopic characterization was carried out by Y. Atilaw, A. Yenesew, A. Ndakala, and M. Erdélyi; antiplasmodial activity assays were done by H.M. Akala and R. Yeda; and cytotoxicity assays were done by Y.J. Wu, P. Coghi, and V.K.W. Wong. All authors contributed to the preparation of the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

#### References

1. De Queiroz, R.T.; Goulart de Azevedo Tozzi, A.M.; Lewis, G.P. Seed morphology: An addition to the taxonomy of *Tephrosia* (Leguminosae, Papilionoideae, Millettieae) from South America. *Plant Syst. Evol.* **2013**, *299*, 459–470. [[CrossRef](#)]
2. Al-Ghamdi, F.A.; Al-Zahrani, R.M. Seed morphology of some species of *Tephrosia* Pers. (Fabaceae) from Saudi Arabia Identification of species and systematic significance. *Feddes Repert.* **2010**, *121*, 59–65. [[CrossRef](#)]
3. Hosni, H.; El-Karemy, Z. Systematic revision of Leguminosae in Egypt. 1. *Tephrosia* Pers. *Sendtnera* **1993**, *1*, 245–257.
4. Bosman, M.T.M.; De Haas, A.J.P. A revision of the genus *Tephrosia* (Leguminosae-Papilionoideae) in Malesia. *Blumea-Biodivers. Evol. Biogeogr. Plants* **1983**, *28*, 421–487.
5. Gillett, J.B. Notes on *Tephrosia* in Tropical Africa. *Kew Bull.* **1958**, *13*, 111. [[CrossRef](#)]
6. Neuwinger, H.D. *African Traditional Medicine*; MedPharm Scientific Publishers: Stuttgart, Germany, 2000; pp. 515–516.
7. Kokwaro, J.O. *Medicinal Plants of East Africa*, 3rd ed.; University of Nairobi Press: Nairobi, Kenya, 2009; pp. 185–187.
8. Chang, L.C.; Daniel, C.; Song, L.L.; Fransworth, N.R.; Pezzuto, J.M.; Kinghorn, A.D. Absolute configuration of novel bioactive flavonoids from *Tephrosia purpurea*. *Org. Lett.* **2000**, *2*, 515–518. [[CrossRef](#)] [[PubMed](#)]
9. Hegazy, M.E.; Abd el-Razek, M.H.; Nagashima, F.; Asakawa, Y.; Pare, P.W. Rare prenylated flavonoids from *Tephrosia purpurea*. *Phytochemistry* **2009**, *70*, 1474–1477. [[CrossRef](#)] [[PubMed](#)]
10. Ahmad, V.U.; Ali, Z.; Hussaini, S.R.; Iqbal, F.; Zahid, M.; Abbas, M.; Saba, N. Flavonoids of *Tephrosia purpurea*. *Fitoterapia* **1999**, *70*, 443–445. [[CrossRef](#)]
11. Sinha, B.; Natu, A.A.; Nanavati, D.D. Prenylated favonoids from *Tephrosia purpurea* seeds. *Phytochemistry* **1982**, *21*, 1468–1470. [[CrossRef](#)]
12. Juma, W.P.; Akala, H.M.; Eyase, F.L.; Muiva, L.M.; Heydenreich, M.; Okalebo, F.A.; Gitu, P.M.; Peter, M.G.; Walsh, D.S.; Imbuga, M.; et al. Terpurinflavone: An antiplasmodial flavone from the stem of *Tephrosia purpurea*. *Phytochem. Lett.* **2011**, *4*, 176–178. [[CrossRef](#)]
13. Muiva-Mutisya, L.; Bernard, M.; Matthias, H.; Andreas, K.; Akala, H.M.; Derese, S.; Omosa, L.K.; Yusuf, A.O.; Edwin, K.; Yenesew, A. 6α-Hydroxy-α-toxicarol and (+)-tephrocin with antiplasmodial activities from *Tephrosia* species. *Phytochem. Lett.* **2014**, *10*, 179–183. [[CrossRef](#)]
14. Gulecha, V.; Sivakuma, T. Anticancer activity of *Tephrosia purpurea* and *Ficus religiosa* using MCF 7 cell lines. *Asian Pac. J. Trop. Med.* **2011**, *4*, 526–529. [[CrossRef](#)]



15. Sandhya, S.; Venkata, K.R.; Vinod, K.R.; Rsnakk, C. Assessment of in vitro antacid activity of different root extracts of *Tephrosia purpurea* (L) Pers by modified artificial stomach model. *Asian Pac. J. Trop. Med.* **2012**, *2*, S1487–S1492. [[CrossRef](#)]
16. Jain, A.; Nahata, A.; Santram, L.; Singhai, A.K. Effects of *Tephrosia purpurea* and *Momordica dioica* on streptozotocin-induced diabetic nephropathy in rats. *Biomed. Prev. Nutr.* **2014**, *4*, 383–389. [[CrossRef](#)]
17. Shenoy, S.; Shwetha, K.; Prabhu, K.; Maradi, R.; Bairy, K.L.; Shanbhag, T. Evaluation of antiinflammatory activity of *Tephrosia purpurea* in rats. *Asian Pac. J. Trop. Med.* **2010**, *3*, 193–195. [[CrossRef](#)]
18. Khatri, A.; Garg, A.; Agrawal, S.S. Evaluation of hepatoprotective activity of aerial parts of *Tephrosia purpurea* L. and stem bark of *Tecomella undulata*. *J. Ethnopharm.* **2009**, *122*, 1–5. [[CrossRef](#)] [[PubMed](#)]
19. Chinniah, A.; Mohapatra, S.; Goswami, S.; Mahapatra, A.; Kar, S.K.; Mallavadhani, U.V.; Das, P.K. On the potential of *Tephrosia purpurea* as anti-*Helicobacter pylori* agent. *J. Ethnopharm.* **2009**, *124*, 642–645. [[CrossRef](#)] [[PubMed](#)]
20. Khalid, S.A.; Waterman, P.G. 8-C-Prenylflavonoids from the seed of *Tephrosia bracteolata*. *Phytochemistry* **1981**, *20*, 1719–1720. [[CrossRef](#)]
21. Jang, D.S.; Park, E.J.; Kang, Y.-H.; Hawthorne, M.E.; Vigo, J.S.; Graham, J.G.; Cabieses, F.; Fong, H.H.; Mehta, R.G.; Pezzuto, J.M. Potential cancer chemopreventive flavonoids from the stems of *Tephrosia toxicaria*. *J. Nat. Prod.* **2003**, *66*, 1166–1170. [[CrossRef](#)] [[PubMed](#)]
22. Bedane, K.G.; Kusari, S.; Masesane, I.B.; Spiteller, M.; Majinda, R.R. Flavanones of *Erythrina livingstoniana* with antioxidant properties. *Fitoterapia* **2016**, *108*, 48–54. [[CrossRef](#)] [[PubMed](#)]
23. Waterman, P.G.; Khalid, S.A. The major flavonoids of the seed of *Tephrosia apollinea*. *Phytochemistry* **1980**, *19*, 909–915. [[CrossRef](#)]
24. Lin, C.-F.; Liu, Y.-W.; Kuo, Y.-H.; Shen, C.-C.; Chiou, W.-F.; Chen, C.-C. Two new isoflavones from the tubers of *Apios taiwanianus*. *Phytochem. Lett.* **2016**, *15*, 164–167. [[CrossRef](#)]
25. Yuldashev, M.P.; Batirov, E.S.; Vdovin, A.D.; Abdullaev, N.D. Flavonoids from the aerial parts of *Glycyrrhiza glabra* L. *Izv. Minist. Obraz. Nauki Resp. Kaz., Nats. Akad. Nauk Resp. Kaz., Ser. Khim.* **2000**, *2*, 67–71.
26. Chen, Y.-L.; Wang, Y.-S.; Lin, Y.-L.; Munakata, K.; Ohta, K. Obovatin, obovatin methyl ether and obovatachalcone, new piscicidal flavonoids from *Tephrosia obovata*. *Agric. Biol. Chem.* **1978**, *42*, 2431–2432. [[CrossRef](#)]
27. Gao, J.Y.; Jiang, Y.L.; Niu, L.L.; Li, H.D.; Yin, W.P. Novel isoflavone from the cockroach *Periplaneta americana*. *Chem. Nat. Compd.* **2016**, *52*, 413–416. [[CrossRef](#)]
28. Smalberger, T.; Vleggaar, R.; De Waal, H.L. Tachrosin: A new flavone from *Tephrosia polystachyoides*. *J. S. Afr. Chem. Inst.* **1971**, *24*, 1–12.
29. Yin, R.; Han, K.; Heller, W.; Albert, A.; Dobrev, P.I.; Zazimalova, E.; Schaeffner, A.R. Kaempferol 3-O-rhamnoside-7-O-rhamnoside is an endogenous flavonol inhibitor of polar auxin transport in *Arabidopsis* shoots. *New Phytol.* **2014**, *201*, 466–475. [[CrossRef](#)] [[PubMed](#)]
30. Raya-Gonzalez, D.; Pamatz-Bolanos, T.; Rio-Torres, R.E.D.; Martinez-Munoz, R.E.; Ron-Echeverria, O.; Martinez-Pacheco, M.M. D-(+)-Pinitol, a component of the heartwood of *Enterolobium cyclocarpum* (Jacq.) Griseb. *Z. Naturforsch. C* **2008**, *63*, 922. [[CrossRef](#)] [[PubMed](#)]
31. Nogueira, C.R.; Lopes, L.M.X. Antiplasmodial natural products. *Molecules* **2011**, *16*, 2146–2190. [[CrossRef](#)]
32. Smilkstein, M.; Sriwilaijaroen, N.; Kelly, J.X.; Wilairat, P.; Riscoe, M. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. *Antimicrob. Agents Chemother.* **2004**, *48*, 1803–1806. [[CrossRef](#)] [[PubMed](#)]
33. Okoth, D.A.; Akala, H.M.; Johnson, J.D.; Koorbanally, N.A. Alkyl phenols, alkenyl cyclohexenones and other phytochemical constituents from *Lannea rivae* (chiiov) Sacleux (Anacardiaceae) and their bioactivity. *Med. Chem. Res.* **2016**, *25*, 690–703. [[CrossRef](#)]
34. Wong, V.K.; Li, T.; Law, B.Y.; Ma, E.D.; Yip, N.C.; Michelangeli, F.; Law, C.K.; Zhang, M.M.; Lam, K.Y.; Chan, P.L.; et al. Saikosaponin-d, a novel SERCA inhibitor, induces autophagic cell death in apoptosis-defective cells. *Cell Death Dis.* **2013**, *4*, e720. [[CrossRef](#)] [[PubMed](#)]

**Sample Availability:** Samples of compounds **1**, **4–11** are available from the authors.



© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).